A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001) (NCT05382325)
A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of MK-1484 as a Monotherapy and in Combination With Pembrolizumab in Adult Participants With Advanced or Metastatic Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to assess the safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) of MK-1484 administered as monotherapy and in combination with pembrolizumab (MK-3475) in adults with advanced or metastatic solid tumors.
Who can join: Review the eligibility criteria below.
Location: Sanford Cancer Center ( Site 0005) — Sioux Falls, South Dakota
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (8 Sites)
- Sanford Cancer Center ( Site 0005) — Sioux Falls, South Dakota
- NEXT Oncology ( Site 0001) — San Antonio, Texas
- Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0011) — Toronto, Ontario
- Rambam Health Care Campus-Oncology ( Site 0021) — Haifa,
- Sheba Medical Center-ONCOLOGY ( Site 0020) — Ramat Gan,
- Nederlands Kanker Instituut - Antoni van Leeuwenhoek - NKI-AVL ( Site 0035) — Amsterdam, North Holland
- Erasmus Medisch Centrum-Medical Oncology ( Site 0036) — Rotterdam, South Holland
- Universitair Medisch Centrum Utrecht-Medical Oncology ( Site 0037) — Utrecht,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced or Metastatic Solid Tumors
- A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors — Denver, Colorado
- A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations — San Francisco, California
- Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors — Boston, Massachusetts
- A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors — Birmingham, Alabama
- A Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors — Los Angeles, California
Explore by condition: All Advanced or Metastatic Solid Tumors clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.